Clinical Guidelines

Saudi Lymphoma Group’s Clinical Practice Guidelines for Diagnosis, Management and Follow-up of Patients with Various Types of Lymphoma during the Coronavirus Disease 2019 Pandemic

Musa Alzahrani1, Mubarak M. Al-Mansour2,3, John Apostolidis4, Ahmed Barefah5, Reyad Dada6,7, Ayman Alhejazi8, Yasir Alayed9, Ibraheem Motabi10, Mansoor Radwi11, Hani Al-Hashmi1

1Department of Medicine and Oncology Center, College of Medicine, King Saud University, 2Department of Medicine, College of Medicine, Al-Faisal University, 3Department of Oncology, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, 4Radiation Oncology, College of Medicine, King Saud University, 5Department of Adult Hematology and BMT, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, 6Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, 7Department of Hematology, Faculty of Medicine, King Abdulaziz University, 8Department of Oncology, King Faisal Specialist Hospital and Research Centre, 9Department of Hematology, Faculty of Medicine, University of Jeddah, Jeddah, 10Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, 11Department of Adult Hematology and Stem Cell Transplantation, Oncology Center, King Fahd Specialist Hospital, Dammam, Saudi Arabia

Abstract The Saudi Lymphoma Group had previously published recommendations on the management of the major subtypes of lymphoma. However, the effect the currently ongoing coronavirus disease 2019 (COVID-19) pandemic has on the management of patients with lymphoma has been paramount. Therefore, the Saudi Lymphoma Group has decided to provide clinical practice guidelines for the diagnosis, management and follow-up of patients with various types of lymphoma during the COVID-19 pandemic.

Keywords: COVID-19, guidelines, lymphoma

INTRODUCTION

Severe acute respiratory syndrome-coronavirus-2 is a novel coronavirus that was identified in the late 2019 and rapidly caused a pandemic. The disease caused by this novel virus is designated as coronavirus disease 2019 (COVID-19). The Saudi Lymphoma Group has previously published its clinical practice guidelines for the diagnosis, management and follow-up of all major types of lymphoma. However, during the COVID-19 pandemic, management should be modified to reduce the infection risk and its complications, maintaining reasonable waiting time without compromising the clinical outcomes.9,11

Studies have shown that patients with solid cancers and hematological malignancies, including lymphomas, are at

Access this article online

Quick Response Code:

Website: www.sjmms.net

DOI: 10.4103/sjmms.sjmms_457_20

How to cite this article: Alzahrani M, Al-Mansour MM, Apostolidis J, Barefah A, Dada R, Alhejazi A, et al. Saudi Lymphoma Group’s clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the coronavirus disease 2019 pandemic. Saudi J Med Med Sci 2020;8:227-38.
higher risk of developing the COVID-19 infection.\textsuperscript{[12,13]} For asymptomatic or minimally symptomatic patients, the therapy can be deferred until the COVID-19 threat has resolved. With the current limited and evolving knowledge about this novel virus, balancing individual versus societal benefits and estimating the risk versus benefit of administering myelosuppressive and/or immunosuppressive therapy to lymphoma patients with COVID-19 is the new global reality that poses ethical dilemmas to the medical community. Prioritization and case-by-case discussion is essential to maximize the benefit of any proposed intervention during the COVID-19 pandemic.\textsuperscript{[14‑17]} Currently, guidelines for the management of patients during the pandemic are mainly comprised of recommendations based on expert opinion given the lack of available evidence. Physicians treating patients with lymphoma must make critical decisions in the management of their patients regarding the type of chemotherapy regimen as well as the timing and use of hematopoietic stem cell transplant (SCT). Consensus guidelines are currently needed, especially at a national level, to streamline the management of lymphoma patients and support physicians in making the most appropriate decision.

**METHODOLOGY**

The Saudi Lymphoma Group assigned experts in the field of lymphoma to write clinical practice recommendations, to serve as national lymphoma management guidelines during the COVID-19 pandemic. This guideline is based on the experts’ opinions and review of the evolving knowledge about cancer management during the pandemic. In Phase I, an agreement on the subtypes of lymphoma to be covered and the general layout of the recommendation were achieved through a short survey conducted between the authors of this guideline. Strengths of the general recommendations were considered either as higher or lower priority; however, evidence within these are not categorized by levels given that these are experts’ based recommendations. In Phase II, each member wrote the assigned section of recommendations supported by the available evidence and literature review. In Phase III, each section was independently reviewed by two different members and the changes were incorporated after a collective discussion between the three members. Lastly, after compiling the sections, all members reviewed and approved the final manuscript of the recommendations.

**HODGKIN LYMPHOMA**

**Recommendations**

**Higher priority**

1. Doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is the preferred frontline therapy for the curative-intent treatment of patients with Hodgkin lymphoma (HL)
2. Reduction of the potential bleomycin-induced lung toxicity should be considered for all patients by considering the results of interim positron emission tomography (PET)-guided strategy, as per the RATHL trial\textsuperscript{[18]}
3. Outpatient regimen is preferred for salvage therapy
4. High-dose chemotherapy with autologous SCT should be considered for chemosensitive relapsed HL.

**Lower priority**

1. Implementation of hypofractionation or delay radiation therapy during the pandemic
2. The systemic treatment for patients with palliative-intent therapy should be modified.

**Initial therapy**

**Limited stage**

ABVD alone (total of four cycles) is an effective approach if complete remission has been documented after two cycles according to the interim PET/computed tomography (CT).\textsuperscript{[2,19,20]} This could help eliminate the need for daily radiation treatment visits and avoid the long-term risk of radiotherapy. However, if interim PET/CT is positive, it is recommended to complete the planned two cycles of ABVD plus involved-site radiotherapy (ISRT).\textsuperscript{[21‑24]} If end-of-induction (EOI) PET/CT is still positive for residual disease, it is recommended to re-biopsy, and, if positive, proceed to salvage therapy.\textsuperscript{[25]} Bleomycin could be replaced with brentuximab vedotin, especially in patients with a history or at risk for lung disease.\textsuperscript{[26]}

**Advanced stage**

ABVD (total of six cycles) is the preferred first-line therapy or alternatively replacing bleomycin with brentuximab vedotin.\textsuperscript{[26]} Patients with a negative interim PET/CT after two cycles should continue four additional cycles of AVD.\textsuperscript{[18]} If PET/CT is not available, then a CT scan and gallium scan, if available, can be utilized to assess response after three to four cycles. In clinically responding patients, a total of six cycles should be completed. However, if there is evidence of disease progression, it should be managed as a refractory disease.\textsuperscript{[25]}

**Relapsed refractory disease**

A new biopsy must confirm any suspected relapse. Multiple salvage regimens are available, but most of them are highly myelosuppressive and require hospital admission.\textsuperscript{[25]} Brentuximab vedotin plus bendamustine (BvB) is an outpatient salvage regimen that has been shown
to reduce the disease burden and mobilize stem cells before autologous SCT.\[27\]

As a general rule, SCT is limited to urgent indications. Because HL is a curable disease, autologous SCT should not be delayed, if possible, for transplant-eligible patients. If a decision is made to proceed with autologous SCT, high-dose melphalan (Mel200) as conditioning can preferably be used because it is safe, effective and feasible as an outpatient autologous SCT.\[28,29\] The use of brentuximab vedotin as maintenance therapy for 1 year after autologous SCT is highly recommended for high-risk patients; however, it might be reasonable to delay starting the maintenance therapy for a few months.\[30\] Patients who have confirmed relapse after autologous SCT could be offered other salvage options including immune checkpoint inhibitors (ICIs) such as nivolumab or pembrolizumab, especially as there is no evidence that ICIs are immunosuppressive and avoiding their use in such patients to reduce COVID-19 infections could deprive patients of a highly active class of drugs.\[31\]

**DIFFUSE LARGE B-CELL LYMPHOMA**

**Recommendations**

**High priority**

1. Rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP 21) every 3 weeks is the standard of care for curative-intent treatment of patients with diffuse large B-cell lymphoma (DLBCL).
2. Central nervous system (CNS) prophylaxis with high-dose methotrexate (MTX) is restricted to selected high-risk groups for CNS involvement (e.g., with testicular, adrenal and renal involvement).
3. Subcutaneous rituximab can be considered for patients who tolerated their first intravenous rituximab dose.
4. Encourage outpatient salvage chemotherapy with rituximab, gemcitabine, dexamethasone and cisplatin (R-GDP).
5. Autologous SCT can be considered for transplant-eligible patients with chemosensitive-relapsed DLBCL.

**Low priority**

1. The omission of consolidation radiotherapy to bulky sites of disease at presentation should be considered unless there is a positive PET/CT scan for residual disease at the end of therapy.
2. The systemic treatment with palliative intent for patients who are not eligible for autologous SCT can be modified.
3. Clinical visits for patients in complete remission can be postponed and virtual consultation should be encouraged.

**Limited-stage diffuse large B-cell lymphoma**

It is defined as Ann Arbor Stage I and II and nonbulky disease (<7.5 cm). Patients are stratified according to age-adjusted international prognostic index risk factors to either limited stage without adverse features (normal lactate dehydrogenase [LDH], Eastern Cooperative Oncology Group Performance Status [ECOG PS 0–1]) or limited stage with adverse features (elevated LDH and/or ECOG PS ≥2).\[32,33\]

For patients without adverse features, the recommended therapy is four cycles of R-CHOP 21 without radiotherapy. This recommendation is based on the Phase III FLAYER study, in which four cycles of R-CHOP 21 was not inferior to six cycles of R-CHOP 21, with a relevant reduction in toxicity.\[34\]

For patients with adverse features, the preferred option is a PET-adapted treatment strategy, where PET is performed after the third cycle of R-CHOP 21. Patients with a negative PET/CT receive one additional cycle of R-CHOP 21 (a total of four cycles).\[35\] However, patients with a positive PET/CT receive involved-site radiation therapy (ISRT) of 30-35 Gy. Patients who do not undergo an interim PET/CT receive either six cycles of R-CHOP 21 or three cycles of R-CHOP 21 followed by ISRT.\[36,37\]

**Advanced-stage diffuse large B-cell lymphoma**

It is defined as Ann Arbor Stage III/IV or bulky disease (≥7.5 cm), regardless of the stage. Based on multiple randomized clinical trials, six cycles of R-CHOP 21 remains the preferred regimen for advanced-stage DLBCL.\[38-43\] Subcutaneous rituximab is an acceptable alternative for patients who tolerated the first dose of intravenous rituximab.\[44,45\] We do not recommend consolidated radiotherapy to sites of initial bulky disease; however, the end-of-therapy PET/CT is recommended to guide further management. For patients with a positive PET/CT, ISRT is recommended if a biopsy is not feasible.\[46\]

The average risk of CNS relapse in DLBCL is approximately 2%-5% and expected to accumulate up to 10% for patients with four to six risk factors, based on the CNS-IPI score.\[47,48\] In general, there is no consensus on the number and type of risk factors or the timing of CNS prophylaxis. We suggest administering high-dose intravenous MTX for selected high-risk groups for CNS involvement (e.g., testicular, adrenal or renal involvement).\[49,50\]

**Relapsed or refractory (R/R) diffuse large B-cell lymphoma**

The preferred therapy for first-relapse or primary refractory DLBCL is salvage chemotherapy followed by
the autologous SCT.\textsuperscript{[51]} We suggest outpatient salvage regimen with rituximab, gemcitabine, dexamethasone and cisplatin (R-GDP).\textsuperscript{[52,53]} For transplant-eligible patients, autologous SCT should not be delayed, if possible.

In general, the treatment is palliative for transplant-ineligible patients.\textsuperscript{[54]} However, for selected patients who are transplant ineligible, have relapsed after autologous SCT or have chemoresistant disease and have access to other therapeutic modalities, polatuzumab vedotin plus bendamustine with rituximab is a feasible option, if available. Chimeric antigen receptor T (CAR-T) cell therapy might be considered for selected patients based on a recent recommendation by the collective experience of the CAR T-cell consortium.\textsuperscript{[55-57]}

**INDOLENT LYMPHOMA**

**Recommendations**

**Higher priority**

1. Potential curative radiation can be offered for eligible patients with early-stage disease
2. Rituximab plus CHOP/CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy should be used rather than rituximab plus bendamustine
3. Subcutaneous rituximab should be used instead of the intravenous formulation for eligible patients
4. The use of rituximab maintenance can be delayed during the COVID-19 pandemic.

**Lower priority**

1. Patients with nonbulky early-stage disease and noneligible for potential curative radiotherapy might only be observed
2. Frail patients with significant comorbidities and stable disease might only be observed
3. If treatment is required in frail patients, consider using single-agent rituximab.

**Limited stage**

Grade 1, 2 and 3A: The standard of care for contiguous Stage I and II is potentially curative ISRT, which results in 5-year failure-free progression rates of 74% and 48%, respectively.\textsuperscript{[58]} With these figures, the committee recommends following this approach during the COVID-19 pandemic. Adding rituximab or chemotherapy to radiation lacks an overall survival benefit, and thus it is not recommended.\textsuperscript{[59]} In affected body regions with nonbulky disease where radiation is expected to cause significant morbidity (i.e., abdomen), observation is a reasonable option. Patients with bulky disease may be treated with chemotherapy regimens, as in advanced stages of disease.

**Advanced stage**

Not all patients with newly diagnosed advanced stage disease require initiation of treatment. If the Groupe d’Etude des Lymphomes Folliculaires criteria are fulfilled, treatment shall be discussed.\textsuperscript{[60]} Frail patients with significant comorbidities and stable disease might be observed. If required, they might be started on single-agent rituximab. Eligible patients in whom treatment cannot be deferred due to disease-related complications (i.e., organ compression and effusions), using CHOP or CVP-based chemoimmunotherapy is preferred over bendamustine because it is known to cause long-lasting significant immunosuppression and lymphopenia. Rituximab as an associate might be preferred over other anti-CD20 monoclonal antibodies because it can be given as a subcutaneous formulation and reduces the duration of stay at the hospital. In the RELEVANCE trial, the novel combination of rituximab and lenalidomide (R2) showed lesser Grade 3–4 neutropenia than other chemoimmunotherapy regimens, and thus it is a reasonable alternative as first-line therapy.\textsuperscript{[61]}

**Maintenance**

In the PRIMA trial, rituximab maintenance after R-CHOP or R-CVP induction showed a 17% improvement of progression-free survival compared with the placebo. However, there was an increase of Grade 2–4 infections by 15% in the rituximab arm. There was no difference in the overall survival between both arms.\textsuperscript{[62]} Therefore, maintenance with anti-CD20-directed therapy may be deferred during the COVID-19 pandemic.

**Relapse**

The criteria for initiation of treatment in first line are also applied in the relapsed setting. In addition to the above-listed regimens (RCHOP, RCVP and R2), the oral agent ibrutinib and duvelisib also showed clinical activity. The indication for autologous or allogeneic stem SCT shall be highly restricted and deferred, if possible.

**MANTLE CELL LYMPHOMA**

**Recommendations**

**Higher priority**

1. Watchful waiting is indicated in indolent subtypes of mantle cell lymphoma (MCL)
2. Intensive regimens are justified during the pandemic for high-risk, transplant-eligible MCL patients
3. Less intensive regimens such as R-CHOP or R-CVP (preferred) or less preferred bendamustine–rituximab (B-R) are reasonable options as outpatient regimens
4. Switching to chemotherapy free (off-label use) with Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib is a reasonable alternative in some patients with very high risk for COVID-19.

**Lower priority**

1. Unlike other types of non-HLs, maintenance rituximab can reduce mortality in MCL and is justified to continue during the pandemic.
2. Autologous SCT can be delayed for patients in complete remission.
3. Palliative radiotherapy can be offered to patients with compromised vital organ or for pain relief.

**Initial therapy**

In patients with the non-nodal leukemic form, smoldering or asymptomatic conventional nodal MCL, initial treatment can be deferred with no adverse impact on outcome. However, in patients with symptomatic disease, off-label use of the BTK inhibitors ibrutinib, acalabrutinib or zanubrutinib or the immunomodulatory agent lenalidomide with rituximab could be considered an upfront therapy, if provisional access is approved locally, to avoid hospital visits for intravenous chemotherapy and thus the potential risk of COVID-19. The Phase 3 randomized STiL and Bright studies have clearly demonstrated that B-R is superior to R-CHOP in terms of progression-free survival, but not in the overall survival. Bendamustine is associated with a reduced risk of myelotoxicity and neutropenic fever but increased risk of lymphopenia. Some experts have raised concerns with its use in the COVID-19 pandemic; therefore, treatment decision should be made on an individual basis.

Although maintenance rituximab (M-R) is associated with improved overall survival in patients treated with R-CHOP, delaying its initiation or temporarily discontinuing M-R is advisable, depending on the local risk of COVID-19 epidemiology. The subcutaneous form of rituximab is preferred, avoiding prolonged hospital visits. M-R after induction with B-R is not indicated, due to lack of evidence of any benefit. Aggressive regimens such as fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose MTX and cytarabine (hyper-CVAD/MA), although effective, could be avoided during the pandemic because they are associated with prolonged neutropenia and hospitalization. Delaying or omitting autologous SCT can be considered during the COVID-19 pandemic because of the current risks associated with treatment.

For blastoid and pleomorphic MCL, young and fit patients should be offered intensified high-dose cytarabine-containing regimens (e.g., hyper-CVAD/MTX). The novel agents have modest and short-term activity in this setting, and it is recommended only for patients unfit for chemotherapy.

**Relapsed/refractory disease**

Novel chemotherapy-free BTK inhibitors such as ibrutinib, acalabrutinib or zanubrutinib or the immunomodulatory agent lenalidomide plus rituximab (R²) are recommended, minimizing or avoiding visits to the hospital for treatment. Young, physically fit patients with a Mantle Cell Lymphoma International Prognostic Index high-risk score with or without TP53 mutations or blastoid/pleomorphic variants can be considered for allogeneic SCT. Finally, for patients unfit for treatment, oral corticosteroids and alkylating agents can be offered for symptom relief. Palliative radiotherapy can be offered to patients with compromised vital organs or for pain relief.

**PRIMARY MEDIASTINAL B-CELL LYMPHOMA**

**Recommendations**

**Higher priority**

1. Outpatient regimen such as R-CHOP-21 should be used as the preferred first-line therapy.
2. Radiation can be omitted in patients with an end-of-therapy negative (Deauville score of 1–3) PET scan.

**Lower priority**

1. Patients who are in remission should be monitored by virtual visits to limit the hospital physical visits.
2. If consolidative radiotherapy is considered, it is advisable to delay it in communities with high-risk COVID-19 epidemiology.

**Initial therapy**

For the treatment of PMBCL, as there is no single standard of care, the Group recommends R-CHOP 21 chemotherapy for six cycles as the first-line therapy. This regimen can be given as an outpatient regimen to minimize the need for admission to the health-care facility. The use of protocols that cause more neutropenia and usually require admission to the hospital such as dose-adjusted (DA) etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) is discouraged during this period. DA-EPOCH-R without radiation has shown good event-free survival and overall survival outcomes in a single arm, Phase 2 prospective study. There is no clear evidence for the superiority of DA-EPOCH-R over R-CHOP, which makes R-CHOP a reasonable and safer option.

Regarding radiation postchemoimmunotherapy, several retrospective studies have shown conflicting results.
Regarding its benefit. However, other retrospective studies have shown that patients who achieve negative end-of-therapy PET scan (Deauville score 1–3) tend to have excellent outcomes without radiation. There is also an ongoing clinical trial by the International Extranodal Lymphoma Study Group looking into this question (IELSG-37). Based on the available evidence, it is reasonable to omit radiation in patients who have negative end-of-therapy PET scan. If radiation is considered, it may be delayed in communities with high-risk COVID-19 epidemiology.

**Relapsed refractory disease**

Similar to DLBCL, second-line therapy for relapsed/refractory PMBCL is salvage chemotherapy followed by autologous SCT. We recommend using outpatient salvage chemotherapy regimen such as R-GDP. ICIs such as pembrolizumab, administered at an outpatient basis, may be considered in patients who relapse after two lines of therapy. The off-label outpatient combination of a ICI with brentuximab vedotin can be offered to patients unfit for salvage chemotherapy or refractory disease, if approved at the local institutional level. Careful monitoring of patients is required, as these patients are at a higher risk of developing immune-related adverse events such as lung toxicity and fever, which may mimic COVID-19 symptoms.

**AGGRESSIVE B-CELL LYMPHOMAS**

**Burkitt lymphoma**

**Recommendations**

**Higher priority**

1. High-risk disease (Stage III and IV; LDH > upper limit of normal; ECOG PS ≥2) could be treated with intensified R-CODox-M/IVAC (cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high dose cytarabine) or R-Hyper-C-VAD/MA
2. Six cycles of DA-R-EPOCH plus intrathecal (IT) MTX is an option for patients without CNS involvement
3. Low-risk disease (Stages I and II; normal LDH; ECOG PS ≤1) could be treated with three cycles of DA-R-EPOCH. Cycles 2 and 3 can be administered in the outpatient setting if resources are available
4. Patients not eligible for intensified chemotherapy can be given mini-R-CHOP (six cycles) plus IT MTX
5. Relapse disease should be treated with salvage chemotherapy followed by autologous SCT without delay for patients with chemosensitive disease.

**Lower priority**

1. For patients not eligible for intensive chemotherapy or those with refractory disease, palliative oral corticosteroids and cyclophosphamide can be offered
2. Palliative radiotherapy can be considered for comfort care if vital organs are compromised or for pain relief.

**Management**

Burkitt lymphoma is a highly aggressive lymphoma that is usually curable with intensified treatment. Therefore, for patients fit for therapy, treatment is offered with intent to cure; hence, no modifications in the dosing or timing of standard protocols can be recommended during the COVID-19 pandemic.

High-risk patients could be treated with intensified R-CODox-M/IVAC or R-Hyper-C-VAD/MA, as these regimens are indicated for patients with CNS involvement and associated with a significantly reduced risk of CNS relapse in comparison to DA-R-EPOCH in patients with no CNS involvement at diagnosis. For patients treated with DA-R-EPOCH, the second cycle and beyond can be administered in an outpatient ambulatory setting, if hospital resources are available. On the other hand, for patients with low-risk disease, three cycles of DA-R-EPOCH is adequate treatment and associated with excellent outcome. Chemosensitive relapses after salvage chemotherapy should proceed with autologous SCT. Increased use of granulocyte colony-stimulating factor, as well as antibiotic, pneumocystis pneumonia, antifungal and anti-viral prophylaxis is recommended to reduce the risk of hospital admissions.

**High-grade B-cell lymphoma, not otherwise specified and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (“double-hit” or “triple-hit” lymphomas)**

**Recommendations**

**Higher priority**

9. Intensified protocols such as R-CODox-M/IVAC (cyclophosphamide, doxorubicin, vincristine, MTX/ifosfamide, etoposide, high-dose cytarabine) or R-Hyper-C-VAD/MA are used in high-risk patients with CNS disease
10. For double- and/or triple-hit lymphomas, DA-R-EPOCH is a good option especially at centers with capacity to deliver it in the outpatient setting
11. For high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), the use of R-CHOP is the preferred option
12. R-CHOP or mini-R-CHOP is used for patients unfit for intensified regimens
13. Relapse disease should be treated with salvage chemotherapy followed by autologous SCT without delay for patients with chemosensitive disease.
Lower priority
1. Consolidation radiotherapy can be delayed or omitted in patients who achieve an EOI PET metabolic complete remission after six cycles of treatment
2. CNS prophylaxis with IT MTX or IV high-dose MTX can be omitted in patients with a low/intermediate CNS IPI score
3. Off-label ibrutinib or lenalidomide may also be considered
4. Palliative radiotherapy for patients with disease confined to a single radiation field or for comfort care if vital organ compromised or pain relief
5. Polatuzumab vedotin plus rituximab with bendamustine is an option for patients who fail salvage therapy or relapse after auto-SCT
6. CAR-T cell therapy can be offered to patients with relapsed/refractory disease, when indicated, if patients have access, and preferably tisagenlecleucel, which can potentially be given at an outpatient basis, which has less toxicity.

Management
Patients with HGBL, NOS and HGBL with MYC and BCL2 and/or BCL6 rearrangement (“double-hit” or “triple-hit”), referred to herein as DHL, are considered to have inferior outcome compared to DLBCL, NOS. For DHL, studies have consistently shown that patients treated with R-CHOP have inferior outcome compared to those who receive intensive frontline therapy. Despite limitations of data, DA-R-EPOCH is considered an acceptable treatment option, although IT MTX lacks adequate CNS prophylaxis.

For patients with limited-stage DHL, a multicenter retrospective study showed excellent and noninferior overall survival and progression-free survival outcomes compared with DLBCL when treated with R-CHOP or R-CHOP-like therapy with or without radiation. Therefore, the Group recommends using this approach during the COVID-19 pandemic to limit the hospitalization and prolong neutropenia associated with other intensified regimens.

For patients with MYC-rearranged (MYC-R) limited-stage HGBL, recent data suggest that there is no benefit of intensified therapy over R-CHOP, which should be accounted for when deciding treatment in the COVID-19 pandemic. Moreover, the prognostic impact of MYC-R in DLBCL/HGBL is largely observed in patients with “double-hit” and “triple-hit” disease, in which MYC is translocated to an immunoglobulin (IGH) partner. Therefore, patients with a newly diagnosed DLBCL/HGBL by morphology and with a non-MYC-IGH rearrangement, determined by fluorescence in situ hybridization, are considered as molecular standard risk, and R-CHOP should be considered for these patients, sparing them from the risk of inpatient intensified regimens and mitigate the risks of COVID-19 infection. CAR-T cell therapy, when accessible, is a lifesaving treatment for patients with r/r DLBCL/HGBL, and should not be deferred in the COVID-19 pandemic, after weighing the potential risks and benefits for the patient and accounting for the CAR-T cell recourses and potential disruptions during the pandemic. Finally, for patients considered for radiotherapy, the International Lymphoma Radiation Oncology Group (ILROG) emergency guidelines for therapy of hematological malignancies during the COVID-19 pandemic should be referred for useful guidance to alternative radiation treatment schemes.

RADIATION THERAPY CONSIDERATIONS

Recommendations
Higher priority
1. Radiotherapy should be omitted when the risk of severe outcomes from COVID-19 infection clearly outweigh the benefit of radiotherapy
2. Radiotherapy can be delayed when there is no or little expected adverse effect on outcome from the delay.

Lower priority
a. The radiotherapy course can be shortened with the use of alternative hypofractionation regimens when radiotherapy could not be omitted or delayed
b. Radiotherapy can be potentially used as a bridging measure to delay the need to initiate systemic therapy.

Omitting radiotherapy
When the risk of severe outcomes from COVID-19 infection (aged ≥60 years and/or presence of serious underlying health conditions) outweighs the benefit of radiotherapy, the omission of radiotherapy can be considered. Examples of such situations include palliative indications when medical alternatives can be offered, completely excised localized low-grade lymphomas, completely excised localized nodular lymphocyte-predominant HL and consolidation radiotherapy in patients who achieved a complete remission after chemotherapy for DLBCL or aggressive non-HL.

Delaying radiotherapy
Delaying radiotherapy can be considered in situations where there is little or no expected adverse effect on outcome from the delay. This can include asymptomatic localized low-grade lymphomas, localized nodular
lymphocyte-predominant HL or patients who develop COVID-19 infection prior to starting radiotherapy.

**Shortening the course of radiotherapy**

Shortening the radiotherapy course can be considered when radiotherapy cannot be omitted or delayed, and this is generally achieved using hypofractionation regimens with the aim of maintaining a similar cure or palliation rate without an increase in toxicity. The risks of acute and late toxicity to normal tissues associated with large dose per fraction are currently mitigated by the use of modern conformal radiotherapy techniques. The ILROG applied radiobiological considerations and clinical experience to generate a few suggested altered dose and fractionation schedules.\[^{[83]}\] Examples of such hypofractionated courses include 36 Gy in 12 fractions for chemorefractory HL, 30 Gy in six fractions for aggressive chemorefractory non-HL or solitary plasmacytoma and single-fraction radiotherapy for palliative indications. It is important to note that the proposed shortened courses should always be used with careful consideration and clinical judgment in each individual patient.

**HEMATOPOIETIC STEM CELL TRANSPLANT AND CELLULAR THERAPY**

**Recommendations**

**High priority**

1. Patients with relapsed curable lymphoma who have completed at least two cycles of salvage regimen and deemed to be eligible for high-dose chemotherapy followed by autologous SCT
2. Allogeneic SCT can be carried out when considered curative in patients who achieved CR after relapse postautologous SCT
3. CAR-T cell therapy in relapse-refractory large B-cell lymphoma that is refractory to at least two lines of chemoimmunotherapy
4. All patients should follow the following precautions:
   - Screening of COVID-19, preferably by nasal swab polymerase chain reaction test, during their workup for transplant and 2 days prior to starting the conditioning regimen or the lymphodepleting regimen in CAR-T cell therapy for recipients and before stem cell collection for donors
   - Deferral of patients and donors for at least 3 months if tested positive for COVID-19
   - All patients should be admitted to the hospital in isolation rooms
   - Utilizing virtual clinic in the posttransplant follow-up, whenever possible
   - Limiting visitors and sitters to none, if possible, during the admission period

- Use of growth factors to reduce the neutropenic period.

**Low priority**

a. Consolidation autologous SCT for noncurable intent
b. Allogeneic SCT in indolent cases.

**Stem cell transplant and cellular therapy considerations**

In the current situation of the COVID-19 pandemic, transplant programs face many challenges and transplant physicians are striving to protect patients, donors and staff from complications related to this highly contagious viral infection and at the same time trying to avoid delays in treatment that may harm patients from their underlying primary disease. Both the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy have published recommendations in this context to minimize risks on recipients and donors.\[^{[111,112]}\] Hematopoietic SCT is indicated in the treatment of lymphoma at different stages.

Taking into consideration the necessity of transplant as a potentially curative option for relapsed DLBCL and HL and the aggressiveness of the disease, it is recommended to proceed with the transplant without delay. In patients where autologous SCT is used as consolidation, a delay of 1–2 months is possible. Delay of allogeneic SCT or CAR-T cell therapy in the indications mentioned above is detrimental, and thus transplant should be performed as scheduled. Given the risk of acquiring the COVID-19 infection throughout the transplantation process, patients who are considered for transplant should be tested during the workup and 2 days before starting the conditioning regimen. Similarly, patients considered for CAR-T cell therapy should be tested prior to starting the lymphodepleting regimen. In the setting of allogeneic SCT, donors must be tested during their workup and 2 days before stem cell collection. For patients and donors who test positive for the virus, cellular therapies should be deferred for at least 3 months.\[^{[109,111]}\]

**SUPPORTIVE CARE**

All efforts should be focused on enhancing communication, which helps in supporting patients to be cared for at home and minimize their need to visit emergency room or clinics and minimize patients’ waiting time in all clinical/treatment areas.\[^{[35,38]}\] Home delivery of oral prescriptions and virtual clinics are effective ways to support patients medically and psychologically during this pandemic. There is no known role for prophylactic antiviral therapy for COVID-19 in any patient, including immunosuppressed patients.
Growth factors and prophylactic antibiotics should be considered in all patients, especially in elderly patients and those with chronic medical illnesses to reduce the risk of emergency room visits and admission,\(^{19,13,57}\)

**Acknowledgment**

The authors would like to thank the Saudi Arabia National Cancer Institute for their guidance during this critical time. No specific funding was allocated for this initiative, and all authors declare that they have no competing interests. All authors contributed intellectually to the manuscript and approved the final version to be published.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

REFERENCES

1. Dada R, Al-Mansour M, Alhashmi H, Kandil M, Alhejazi A, Sagheir A, *et al.* Follicular lymphoma: Saudi lymphoma group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:214-8.

2. Alhashmi H, Kandil M, Alhejazi A, Motabi I, Sagheir A, Alzahrani M, *et al.* Hodgkin’s lymphoma: Saudi Lymphoma Group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:195-201.

3. Alzahrani M, Sagheir A, Motabi I, Dada R, Al-Mansour M, Alhashmi H, *et al.* Mantle cell lymphoma: Saudi Lymphoma Group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:226-30.

4. Kandil M, Alhashmi H, Alzahrani M, Alhejazi A, Motabi I, Dada R, *et al.* Marginal zone lymphoma: Saudi Lymphoma Group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:202-8.

5. Motabi I, Alzahrani M, Dada R, Al-Mansour M, Alhashmi H, Kandil M, *et al.* Natural Killer/T-Cell lymphoma: Saudi Lymphoma group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:222-5.

6. Al-Mansour M, Dada R, Kandil M, Sagheir A, Alzahrani M, Alhejazi A, *et al.* Diffuse large B-cell lymphoma: Saudi Lymphoma group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:209-13.

7. Sagheir A, Alhejazi A, Al-Mansour M, Alhashmi H, Kandil M, Motabi I, *et al.* Primary central nervous system lymphoma: Saudi Lymphoma Group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:219-21.

8. Alhejazi A, Motabi I, Sagheir A, Alzahrani M, Dada R, Al-Mansour M, *et al.* Primary mediastinal large B-cell lymphoma: Saudi lymphoma group’s clinical practice guidelines for diagnosis, management and follow-up. Saudi J Med Med Sci 2019;7:231-3.

9. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, *et al.* COVID-19 in persons with haematological cancers. Leukemia 2020;34:1637-45.

10. Perini GF, Fischer T, Gaillard RD, Rocha TB, Bellesso M, Teixeira LLC, *et al.* How to manage lymphoma malignancies during novel 2019 coronavirus (CoVid-19) outbreak: A Brazilian task force recommendation. Hematol Transfus Cell Ther 2020;42:103-10.

11. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, *et al.* Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020;21:335-7.

12. Yu J, OuYang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020;6:1108-10.

13. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21:e180.

14. Percival M, Lynch R, Halpern A, Shadman M, Cassaday R, Uijiani C, *et al.* Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: The Seattle Strategy. JCO Oncol Pract 2020. pii: OP2000241. doi: 10.1200/OP20.00241

15. Wei W, Zheng D, Lei Y, Wu S, Verma V, Liu Y, *et al.* Radiotherapy workflow and protection procedures during the Coronavirus Disease 2019 (COVID-19) outbreak: Experience of the Hubei Cancer Hospital in Wuhan, China. Radiother Oncol 2020;148:203-10.

16. Ueda M, Martins R, Hendrie PC, McDowell T, Crews JR, Wong TL, *et al.* Managing cancer care during the COVID-19 pandemic: Agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020;18:1-4.

17. National Health Service England. Clinical Guide for the Management of Noncoronavirus Patients Requiring Acute Treatment: Cancer; March 23, 2020. Available from: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf. [Last accessed on 2020 Apr 01]

18. Johnson P, Federico M, Kirkwood A, Fossa S, Berkahn L, Carella A, *et al.* Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016;374:2419-29.

19. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 2018;93:704-15.

20. Hutchings M. PET-adapted treatment of Hodgkin lymphoma. Blood 2019;134:1201-0.

21. Raemackers J, André M, Federico M, Girinsky T, Omedaly R, Brusamolino E, *et al.* Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIIL H10 trial. J Clin Oncol 2014;32:1188-94.

22. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, *et al.* Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 2015;372:1598-607.

23. Canellos G, Abramson J, Fisher D, LaCasce A. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010;28:1611-5.

24. Meyer R, Gospodarowicz M, Connors J, Pearcey R, Wells W, Winter J, *et al.* ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012;366:399-408.

25. Nikolaoenko I, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol 2017;8:293-302.

26. Connors J, Jureczak W, Straus D, Ansell S, Kim W, Gallamini A, *et al.* Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378:1598-607.

27. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, *et al.* Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed refractory Hodgkin lymphoma. Blood 2018;123:40-8.

28. Stewart D, Guo D, Sunderland J, Ruether B, Jones A, Poon M, *et al.* Single-agent high-dose melphalan salvage therapy for Hodgkin’s disease: Cost, safety, and long-term efficacy. Ann Oncol 1997;8:1277-9.

29. Kaloyanidou P, Al Hashmi H, Rauf M, Maghsour I, Salman H, Kafars S, *et al.* BEAM versus single agent high dose melphalan (HD) conditioning regimen for autologous hematopoietic stem cell transplant (ASCT): A retrospective matched analysis in relapse/refractory Hodgkin lymphoma. Biol Blood Marrow Transpl 2019;25:8187-8.
et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853-62.

33. Kattan J, Kattan C, Assi T. Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection? Immunotherapy 2020;12:351-4.

34. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.

35. Ziepert M, Hasenele-Duh K, Ehn H, Glass B, Schmitt N, Pfleundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373-80.

36. Poessel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): A randomised, phase 3, non-inferiority trial. Lancet 2020;394:2271-81.

37. Lamy T, Damaj G, Soubeyran P, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky large B-cell lymphoma. Blood 2018;131:174-81.

38. Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MahThera International Trial (MThT) Group. Lancet Oncol 2011;12:1013-22.

39. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303. J Clin Oncol 2019;37:1790-9.

40. Dacruz R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-GB study): A randomised phase 3 trial. Lancet Oncol 2013;14:525-33.

41. Récher C, Coiffier B, Haïoun C, Molina TJ, Ferré C, Casassavous O, et al. Intensified chemotherapy with ACVB plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LN03-2B): An open-label randomised phase 3 trial. Lancet 2011;378:1858-67.

42. Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in young patients with good-prognosis diffuse large-B-cell lymphoma (the LNH03-GB study): A randomised phase 3 trial. Lancet Oncol 2013;14:525-33.

43. Offner F, Samolowska O, Osmanov E, Eom HS, Topp MS, Raposo J, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 2015;126:1893-901.

44. Davies A, Merli F, Mihaljevic B, Sritanaratkul N, Solal-Céligny P, Barrett M, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): Stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014;15:343-52.

45. Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+diffuse large B-cell lymphoma or follicular lymphoma: Results from a prospective, randomized, open-label, crossover study (PreFMab). Ann Oncol 2017;28:836-42.

46. Dabaja BS, Vanderplas AM, Cvoeryl-Thompson AL, Abel GA, Czeuzman MS, Friedberg JW, et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer 2015;121:1032-9.

47. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: A risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol 2016;34:3150-6.

48. El-Galaly TC, Villa D, Michaelson TY, Hutchings M, Mikaelis NG, Savage KJ, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemotherapy. Oncology (Williston Park) 2018;32:303-9.

49. Philip T, Guglielmetti C, Hagenbeek A, Somers R, Van der Helie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;339:21-6.

50. Dada R. Diagnosis and management of follicular lymphoma: Results from a prospective, randomized, open-label, crossover study (PreFMab). Ann Oncol 2015;26:1239-46.
A randomized study from the Groupe d’Etude des Lymphomes Folliculaires, Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15:1110-7.

61. Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379:934-47.

62. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011;377:42-51.

63. Kluin-Nelemans H, Hoster E, Hermine O, Walewski J, Trneny W, Geiser C, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367:520-31.

64. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-13.

65. Navarro A, Clot G, Roca C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72:3307-16.

66. Ye H, Desai A, Zeng D, Nomico K, Romaguera J, Ahmed M, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res 2017;36:185.

67. Royo C, Navarro A, Clot G, Salverstra I, Giné E, Jares P, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012;26:1895-8.

68. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial. Lancet 2016;387:148-56.

69. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33:2762-6.

70. Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine kinase. Clin Cancer Res 2020;37 Suppl 2:4-5.

71. Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood 2018;132:2016-25.

72. Rummel A, Bashmeyer G, Ganser A, Heider A, Gruenenhagen U, Losen C, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. J Clin Oncol 2016;34:1176-87.

73. Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP. Results of the BRIGHT 5-year follow-up study. J Clin Oncol 2019;37:984-91.

74. Romaguera JE, Fayad I, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23.

75. Visco C, Chiappella A, Nasi I, Patti C, Ferrero S, Barbero D, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: A multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol 2017;4:e15-23.

76. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-84.

77. Zouler A, Unterhalt M, Stilgenbauer S, Hubel K, Thieblemont C, Metzner B, et al. Autologous stem cell transplantation in first remission significantly prolongs progression-free and overall survival in mantle cell lymphoma. Haematol Oncol 2019;37 Suppl 2:24-34.

78. Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: Still a diagnostic and therapeutic challenge! Blood 2018;132:2722-9.

79. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: A pooled analysis from three open-label studies. Br J Haematol 2017;179:430-8.

80. Dreger P, Michallet M, Bosman P, Dietrich S, Sohbi M, Boumendil A, et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: A study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplant 2019;54:44-52.

81. Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: A retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant 2018;53:17-24.

82. Lin RJ, Ho C, Hilden PD, Barker JN, Girah SA, Hamlin PA, et al. Allogeneic hematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol 2019;184:1006-10.

83. Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhael NG, Vogelius IR, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood 2020;135:1829-32.

84. Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664-70.

85. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408-16.

86. Jackson MW, Rusthoven CG, Jones BL, Kamdar M, Rabinovitch R. Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma. Am J Hematol 2016;91:476-80.

87. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. Ann Oncol 2006;17:123-30.

88. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, et al. Treatment of primary mediastinal large B-cell lymphoma who achieve complete metabolic response with radiotherapy. Cancer Res 2012;72:5307-16.

89. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, et al. Primary mediastinal B-cell lymphoma: A phase 3, randomised controlled trial. Ann Oncol 2011;22:664-70.

90. Zinzani PL, Broccoli A, Casadei B, Stefoni V, Pellegrini C, Gandolfi L, et al. Pembrolizumab in relapsed or refractory mantle-cell lymphoma: The emerging standard of care. Oncologist 2012;17:239-49.

91. Savage K, Venson P, Shenker T, Klasa R, Villa D, Goktepe O, et al. The outcome of primary mediastinal large B-Cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 2012;120:303.

92. Zinzani PL, Broccoli A, Casadei B, Stefoni V, Pellegrini C, Gandolfi L, et al. Outcomes of patients with relapsed or refractory mantle cell lymphoma: Role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma. Hematol Oncol 2015;33:145-50.

93. Sayed A, Apostolidis J, Al-Hindi T, Al-Rawais F, Naim A, Mokhtar N, et al. Can radiotherapy be safely omitted in patients with primary mediastinal B-cell lymphoma who achieve complete metabolic response after chemoimmunotherapy? A retrospective analysis from a single center. Hemasphere 2020;4 Suppl 1:EP1276.

94. Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-Cell lymphoma. J Clin Oncol 2019;37:3291-9.

95. Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with brentuximab vedotin for relapsed/
refractory primary mediastinal large B-cell lymphoma: Efficacy and safety from the phase II Checkmate 456 study. J Clin Oncol 2019;37:3081-9.

94. Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. Blood 2014;124:2913-20.

95. Zayac A, Evans A, Stadnik A, Smith S, Jagadeesh D, Leslie L, et al. Outcomes of patients with newly-diagnosed Burkitt lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: A multi-institutional real-world analysis. Blood 2019;134 Suppl 1:402.

96. Evans A, Danilov A, Jagadeesh D, Sperling A, Kim S, Vaca R, et al. The evaluation and treatment of Burkitt lymphoma in the modern era: Real world outcomes and prognostication across 26 US Cancer Centers. Blood 2019;134 Suppl 1:397.

97. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol 2020;JCO2000303. Online ahead of print.

98. Keshvani N, Hon M, Gupta A, Brown TJ, Roy L, Marley E, et al. Reducing hospitalizations: Institution of outpatient infusional EPOCH-based chemotherapy at a safety net hospital. J Oncol Pract 2019;15:e644‑51.

99. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2020;382:1915‑25.

100. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis. Blood 2014;124:2354-61.

101. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol 2017;35:2260‑7.

102. Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: A prospective, multicentre, single-arm phase 2 study. Lancet Haematol 2018;5:e609‑17.

103. Friedberg JW. How I treat double-hit lymphoma. Blood 2017;130:590-6.

104. Barraclough A, Alzahrani M, Eitrun M, Bishon M, van Vliet C, Farhima P, et al. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: A retrospective multicenter study. Blood Adv 2019;3:2013-21.

105. Torka P, Kothari S, Sundaram S, Li S, Medenios I, Ayers E, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Adv 2020;4:253-62.

106. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borochmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380:45‑56.

107. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531‑44.

108. Ljungman P, Mikulska M, de la Camara R, Basak G, Chabannon C, Duarta R, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant 2020;1‑6. [doi: 10.1038/s41409‑020‑0919‑0].

109. ASCCTS. Interim Guidelines for COVID-19 Management in Hematopoietic Cell Transplant and Cellular Therapy Patients Version 1.3; April 16, 2020. Available from: https://www.asctc.org/ [Last accessed 2020 Jun 20].